# Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.

> **NCT04909515** · PHASE2 · WITHDRAWN · sponsor: **Y-mAbs Therapeutics**

## Conditions studied

- Neuroblastoma

## Interventions

- **DRUG:** Naxitamab
- **DRUG:** GM-CSF
- **DRUG:** Isotretinoin

## Key facts

- **NCT ID:** NCT04909515
- **Lead sponsor:** Y-mAbs Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12-02
- **Primary completion:** 2026-06
- **Final completion:** 2027-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study terminated due to business priorities
- **Last updated:** 2022-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04909515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04909515, "Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04909515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*